Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Pd-1/Pd-L1 Blockade Therapy With Atezolizumab: A New Paradigm in the Treatment of Non-Small Cell Lung Cancer (Nsclc) Publisher



Moradi S1 ; Sarikhani P2 ; Albadr RJ3 ; Taher WM4 ; Alwan M5 ; Jawad MJ6 ; Mushtaq H7 ; Vakilzadehian N8
Authors

Source: Discover Oncology Published:2025


Abstract

Now, platinum-based chemotherapy is used as the first-line treatment for advanced non-small cell lung cancer (NSCLC). Interestingly, a combination of immune checkpoint inhibitors, such as mepolizumab, with other targeted therapies and chemotherapy help to make a significant improvement. Atezolizumab, a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1), blocks PD-1 activation and results in T-cell activity against tumor cells. As the second-line treatment of advanced or metastatic NSCLC, atezolizumab plus chemotherapy was approved in 2017 concerning the clinical benefit of the phase III OAK trials. Atezolizumab, compared with docetaxel, remarkably increased overall survival (OS) and showed promising efficacy and tolerability in the treatment of advanced NSCLC.Research on atezolizumab's application in neoadjuvant (pre-surgery) and adjuvant (post-surgery) contexts is ongoing. It is now undergoing trials to assess its efficacy in these settings, which may broaden its place in the NSCLC therapy spectrum and enhance long-term results. This paper briefly summarizes the clinical data of atezolizumab therapy alone or in combination with other therapeutics for NSCLC therapy. © The Author(s) 2025.
Related Docs
View other Related Docs
1. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)
2. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
3. Tumor Immunology, Clinical Immunology (2022)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (6)
Shekoufeh Nikfar (1)
Other Related Docs
4. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
5. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
6. Nivolumab and Pembrolizumab As Immune-Modulating Monoclonal Antibodies Targeting the Pd-1 Receptor to Treat Melanoma, Expert Review of Anticancer Therapy (2015)
7. Immune Checkpoint Inhibitors in Cancer Therapy, Current Oncology (2022)
8. Comprehensive Multi-Omics Analysis Reveals Npc2 and Itgav Genes As Potential Prognostic Biomarkers in Gastrointestinal Cancers, Cancer Reports (2024)
9. The Safety and Efficacy of Anti-Pd-1/Pd-L1 Monoclonal Antibodies for Lung Cancer Brain Metastasis: A Systematic Review and Meta-Analysis on Brain Metastasis, Neurosurgical Review (2025)
10. Discovering Tumor Microenvironment Dynamics in Hpv-Associated Cancers: Using Organoid-Based Models to Develop Therapeutics, Regenerative Engineering and Translational Medicine (2025)
11. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
12. Expression of Pd1 and Pdl1 As Immune-Checkpoint Inhibitors in Mantle Cell Lymphoma, BMC Cancer (2022)
13. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
14. Imidazo[1,2-A]Quinazolines As Novel, Potent Egfr-Tk Inhibitors: Design, Synthesis, Bioactivity Evaluation, and in Silico Studies, Bioorganic Chemistry (2023)
15. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)
16. Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial, BMC Cancer (2022)
17. Advances in Therapeutic Targeting of Immune Checkpoints Receptors Within the Cd96-Tigit Axis: Clinical Implications and Future Perspectives, Expert Review of Clinical Immunology (2022)
18. Immunogenic Cell Death (Icd)-Inducers in Non-Small-Cell Lung Carcinoma (Nsclc): Current Knowledge and Future Perspective, Clinical and Translational Oncology (2023)
19. Bispecific Therapeutics: A State-Of-The-Art Review on the Combination of Immune Checkpoint ‎Inhibition With Costimulatory and Non-Checkpoint Targeted Therapy, Expert Opinion on Biological Therapy (2024)
20. Immunotherapeutic Approaches for Cancer Therapy: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)